Published in N Engl J Med on September 17, 2007
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int (2014) 5.17
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int (2008) 4.73
Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int (2008) 3.80
Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int (2009) 3.74
Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study. Osteoporos Int (2012) 3.13
Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc (2008) 2.66
Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc (2010) 2.32
Quality of osteoporosis care of older Medicare recipients with fragility fractures: 2006 to 2010. J Am Geriatr Soc (2013) 2.08
Validation of a short questionnaire for estimating dietary calcium intakes. Osteoporos Int (2014) 2.06
Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporos Int (2013) 2.05
Secular trends in hip fracture incidence and recurrence. Osteoporos Int (2008) 2.04
NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw (2009) 1.97
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int (2010) 1.83
Clinical risk factors, bone density and fall history in the prediction of incident fracture among men and women. Bone (2012) 1.82
Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int (2011) 1.77
Bone regenerative medicine: classic options, novel strategies, and future directions. J Orthop Surg Res (2014) 1.64
Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician (2014) 1.63
Clinical effectiveness of orthogeriatric and fracture liaison service models of care for hip fracture patients: population-based longitudinal study. Age Ageing (2016) 1.58
Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ (2008) 1.54
Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study. J Bone Miner Res (2014) 1.52
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res (2016) 1.50
Mortality rates after incident non-traumatic fractures in older men and women. Osteoporos Int (2010) 1.46
The role of zoledronic acid in the management of osteoporosis. Clin Rheumatol (2010) 1.44
Drugs, medications and periodontal disease. Br Dent J (2014) 1.44
Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. J Bone Miner Res (2013) 1.44
UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos (2017) 1.40
Targeting cellular senescence prevents age-related bone loss in mice. Nat Med (2017) 1.39
Osteoporosis, frailty and fracture: implications for case finding and therapy. Nat Rev Rheumatol (2012) 1.28
The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int (2014) 1.27
Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int (2010) 1.25
A review of drug-induced hypocalcemia. J Bone Miner Metab (2009) 1.23
Does a history of non-vertebral fracture identify women without osteoporosis for treatment? J Gen Intern Med (2008) 1.23
Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice. Clin Interv Aging (2008) 1.22
High-dose oral vitamin D3 supplementation in the elderly. Osteoporos Int (2008) 1.20
Zoledronic acid and secondary prevention of fractures. N Engl J Med (2007) 1.19
Risk of subsequent fracture and mortality within 5 years after a non-vertebral fracture. Osteoporos Int (2010) 1.18
Hip fracture incidence is decreasing in the high incidence area of Oslo, Norway. Osteoporos Int (2012) 1.18
Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int (2010) 1.17
Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc (2010) 1.16
Short- and long-term mortality in males and females with fragility hip fracture in Norway. A population-based study. Clin Interv Aging (2013) 1.14
The real enemy is fragility fracture, not osteoporosis. Osteoporos Int (2015) 1.13
Depression as a risk factor for osteoporosis. Trends Endocrinol Metab (2009) 1.13
Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women MESA (The Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol (2010) 1.12
A guide to improving the care of patients with fragility fractures. Geriatr Orthop Surg Rehabil (2011) 1.12
Prevention of osteoporosis-related fractures among postmenopausal women and older men. CMAJ (2009) 1.12
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag (2010) 1.12
Orthopedic surgeon's awareness can improve osteoporosis treatment following hip fracture: a prospective cohort study. J Korean Med Sci (2011) 1.08
A Guide to Improving the Care of Patients with Fragility Fractures, Edition 2. Geriatr Orthop Surg Rehabil (2015) 1.08
The potential economic benefits of improved postfracture care: a cost-effectiveness analysis of a fracture liaison service in the US health-care system. J Bone Miner Res (2014) 1.08
Treatment of osteoporosis in men. Bone (2012) 1.06
Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide. J Bone Miner Metab (2014) 1.06
Is withholding osteoporosis medication after fracture sometimes rational? A comparison of the risk for second fracture versus death. J Am Med Dir Assoc (2010) 1.06
The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml. Osteoporos Int (2012) 1.05
The Osteoporosis Self-Assessment Tool versus alternative tests for selecting postmenopausal women for bone mineral density assessment: a comparative systematic review of accuracy. Osteoporos Int (2008) 1.05
Health-related quality of life after vertebral or hip fracture: a seven-year follow-up study. BMC Musculoskelet Disord (2009) 1.05
Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol (2011) 1.04
Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases. Drug Des Devel Ther (2009) 1.03
Aging and bone loss: new insights for the clinician. Ther Adv Musculoskelet Dis (2012) 1.02
Comparison of published orthopaedic trauma trials following registration in Clinicaltrials.gov. BMC Musculoskelet Disord (2011) 1.01
Closing the osteoporosis care gap: increased osteoporosis awareness among geriatrics and rehabilitation teams. BMC Geriatr (2009) 1.01
Mortality and osteoporotic fractures: is the link causal, and is it modifiable? Clin Exp Rheumatol (2008) 1.00
Closing the gap in postfracture care at the population level: a randomized controlled trial. CMAJ (2011) 1.00
Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J Clin Endocrinol Metab (2009) 0.99
Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients. Osteoporos Int (2010) 0.99
Current and future treatment options in osteoporosis. Eur J Clin Pharmacol (2011) 0.98
A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int (2011) 0.98
Bisphosphonate-associated osteonecrosis of the jaw. Can Fam Physician (2008) 0.98
Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet Disord (2009) 0.98
Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials. Osteoporos Int (2009) 0.97
Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int (2010) 0.97
The relation between bisphosphonate use and non-union of fractures of the humerus in older adults. Osteoporos Int (2008) 0.97
Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int (2010) 0.97
What's in a name? What constitutes the clinical diagnosis of osteoporosis? Osteoporos Int (2012) 0.95
SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass. Aging Cell (2014) 0.94
Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporos Int (2010) 0.94
Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int (2010) 0.94
Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer. Clin Breast Cancer (2010) 0.93
Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women. Osteoporos Int (2011) 0.93
Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Osteoporos Int (2011) 0.92
Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients-a nationwide register-based open cohort study. Osteoporos Int (2012) 0.92
Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years? J Transl Med (2013) 0.92
Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management. Drug Healthc Patient Saf (2010) 0.92
Current, new and future treatments of osteoporosis. Rheumatol Int (2010) 0.92
A review of periprosthetic femoral fractures associated with total hip arthroplasty. Geriatr Orthop Surg Rehabil (2012) 0.92
Zoledronic acid and atrial fibrillation in cancer patients. Support Care Cancer (2010) 0.92
Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications. Osteoporos Int (2012) 0.91
Is bone quality associated with collagen age? Osteoporos Int (2009) 0.91
Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial. Osteoporos Int (2014) 0.90
Testing and treatment for osteoporosis following hip fracture in an integrated U.S. healthcare delivery system. Osteoporos Int (2011) 0.90
Maximising functional recovery following hip fracture in frail seniors. Best Pract Res Clin Rheumatol (2013) 0.90
Intravenous bisphosphonates for postmenopausal osteoporosis. J Res Med Sci (2010) 0.90
Diagnosis and management of osteoporosis in the older senior. Clin Interv Aging (2009) 0.90
Cardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional links. Clin Interv Aging (2013) 0.89
Management of osteoporosis among home health and long-term care patients with a prior fracture. South Med J (2009) 0.89
Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report. Spec Care Dentist (2010) 0.89
Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study. Am J Med (2015) 0.89
Vitamin D deficiency. N Engl J Med (2007) 59.34
A multiple testing procedure for clinical trials. Biometrics (1979) 26.80
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res (1993) 10.98
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Hip fractures in the elderly: a world-wide projection. Osteoporos Int (1992) 9.08
Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int (1998) 7.14
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc (2006) 5.32
Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res (1997) 4.74
Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med (2002) 4.20
Recovery from hip fracture in eight areas of function. J Gerontol A Biol Sci Med Sci (2000) 4.19
Mortality and locomotion 6 months after hospitalization for hip fracture: risk factors and risk-adjusted hospital outcomes. JAMA (2001) 3.13
Interventions to improve osteoporosis treatment following hip fracture. A prospective, randomized trial. J Bone Joint Surg Am (2005) 3.12
Excess mortality attributable to hip fracture in white women aged 70 years and older. Am J Public Health (1997) 2.68
Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone (2005) 2.66
Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture. Am J Med (2000) 2.62
Prevention and management of osteoporosis. World Health Organ Tech Rep Ser (2003) 2.48
The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int (2001) 2.32
Standardization of bone mineral density at femoral neck, trochanter and Ward's triangle. Osteoporos Int (2001) 2.25
Hip fracture incidence among the old and very old: a population-based study of 745,435 cases. Am J Public Health (1990) 2.00
The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int (2003) 1.97
Functional outcome and quality of life following hip fracture in elderly women: a prospective controlled study. Osteoporos Int (2003) 1.91
Randomized trial to improve fracture prevention in nursing home residents. Am J Med (2007) 1.75
Interventions to improve medication compliance in older patients living in the community: a systematic review of the literature. Drugs Aging (2003) 1.58
Underuse of osteoporosis medications in elderly patients with fractures. Am J Med (2003) 1.57
Hip fracture mortality and morbidity--can we do better? N Z Med J (2001) 1.35
The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair. Curr Med Res Opin (2004) 1.15
A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A (2004) 44.81
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med (2007) 7.60
Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet (2009) 6.66
Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med (2014) 6.56
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47
Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med (2010) 6.13
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell (2009) 5.74
Analyses of pig genomes provide insight into porcine demography and evolution. Nature (2012) 5.58
Lanthanide-transition-metal sandwich framework comprising {Cu3} cluster pillars and layered networks of {Er36} wheels. Angew Chem Int Ed Engl (2005) 4.93
Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med (2007) 4.68
Unsupervised learning of an atlas from unlabeled point-sets. IEEE Trans Pattern Anal Mach Intell (2004) 4.63
Cross-leg flaps: our preferred alternative to free flaps in the treatment of complex traumatic lower extremity wounds. J Am Coll Surg (2013) 4.30
ncRNA- and Pc2 methylation-dependent gene relocation between nuclear structures mediates gene activation programs. Cell (2011) 4.26
Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med (2010) 4.24
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature (2007) 4.12
A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum (2012) 4.01
Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med (2009) 3.97
Functional roles of enhancer RNAs for oestrogen-dependent transcriptional activation. Nature (2013) 3.93
Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis. Nature (2003) 3.72
Recognizing names in biomedical texts: a machine learning approach. Bioinformatics (2004) 3.70
Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab (2008) 3.67
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med (2005) 3.57
Expression analysis of G Protein-Coupled Receptors in mouse macrophages. Immunome Res (2008) 3.54
Genomic analyses identify distinct patterns of selection in domesticated pigs and Tibetan wild boars. Nat Genet (2013) 3.41
Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet (2012) 3.40
Death or hospitalization of patients on chronic hemodialysis is associated with a physician-based diagnosis of depression. Kidney Int (2008) 3.34
The phosphothreonine lyase activity of a bacterial type III effector family. Science (2007) 3.18
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med (2012) 3.14
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol (2003) 3.10
Circadian and CLOCK-controlled regulation of the mouse transcriptome and cell proliferation. Proc Natl Acad Sci U S A (2007) 3.06
Dorsal root ganglion neurons innervating skeletal muscle respond to physiological combinations of protons, ATP, and lactate mediated by ASIC, P2X, and TRPV1. J Neurophysiol (2008) 2.99
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol (2012) 2.98
Pseudomonas syringae effector AvrPto blocks innate immunity by targeting receptor kinases. Curr Biol (2007) 2.84
Porous lanthanide-organic open frameworks with helical tubes constructed from interweaving triple-helical and double-helical chains. Angew Chem Int Ed Engl (2005) 2.83
Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg (2008) 2.79
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc (2008) 2.75
Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ (2009) 2.64
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res (2011) 2.53
Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum (2009) 2.50
Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. J Am Coll Cardiol (2007) 2.47
Effect of 6-month whole body vibration training on hip density, muscle strength, and postural control in postmenopausal women: a randomized controlled pilot study. J Bone Miner Res (2003) 2.47
Recognition of protein/gene names from text using an ensemble of classifiers. BMC Bioinformatics (2005) 2.42
The effect of comorbid illness on receipt of cancer screening by older people. J Am Geriatr Soc (2002) 2.42
Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med (2003) 2.41
Homeodomain-mediated beta-catenin-dependent switching events dictate cell-lineage determination. Cell (2006) 2.40
Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. Am J Transplant (2004) 2.35
Gene set enrichment in eQTL data identifies novel annotations and pathway regulators. PLoS Genet (2008) 2.32
Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int (2008) 2.29
Association of hypogonadism with vitamin D status: the European Male Ageing Study. Eur J Endocrinol (2011) 2.28
Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. Cancer (2012) 2.24
Quantifying data quality for clinical trials using electronic data capture. PLoS One (2008) 2.19
Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly. Am J Med (2004) 2.18
Meta-analysis added power to identify variants in FTO associated with type 2 diabetes and obesity in the Asian population. Obesity (Silver Spring) (2010) 2.15
Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong? J Bone Miner Res (2004) 2.15
Modulation of cardiac gap junction expression and arrhythmic susceptibility. Circ Res (2004) 2.11
Subcellular heterogeneity of sodium current properties in adult cardiac ventricular myocytes. Heart Rhythm (2011) 2.10
Accumulation of free ADP-ribose from mitochondria mediates oxidative stress-induced gating of TRPM2 cation channels. J Biol Chem (2004) 2.08
Diverse CD81 proteins support hepatitis C virus infection. J Virol (2006) 2.07
[The vitamin D status of the Danish population needs to be improved]. Ugeskr Laeger (2005) 2.07
Superfamily phenomena and motifs of networks induced from time series. Proc Natl Acad Sci U S A (2008) 2.06
Androgens and bone. Endocr Rev (2004) 2.06
Hematoma resolution as a target for intracerebral hemorrhage treatment: role for peroxisome proliferator-activated receptor gamma in microglia/macrophages. Ann Neurol (2007) 2.05
The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther (2007) 2.05
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res (2008) 2.04
Effect of thimerosal on the neurodevelopment of premature rats. World J Pediatr (2013) 2.04
A series of luminescent lanthanide-cadmium-organic frameworks with helical channels and tubes. Chem Commun (Camb) (2006) 2.01
Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab (2010) 2.01
Hemiarthroplasty or internal fixation for intracapsular displaced femoral neck fractures: randomised controlled trial. BMJ (2007) 1.98
Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 1.98
Jamming by shear. Nature (2011) 1.98
Age-related differences in unruptured intracranial aneurysms: 1-year outcomes. J Neurosurg (2014) 1.96
Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med (2011) 1.95
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone (2007) 1.94
A germanate framework containing 24-ring channels, Ni--Ge bonds, and chiral [Ni@Ge14O24(OH)3] cluster motifs transferred from chiral metal complexes. Angew Chem Int Ed Engl (2005) 1.94
Flagellin induces innate immunity in nonhost interactions that is suppressed by Pseudomonas syringae effectors. Proc Natl Acad Sci U S A (2005) 1.94
High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res (2005) 1.94
Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program. Arthritis Care Res (Hoboken) (2013) 1.92
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res (2012) 1.92
Exome sequencing reveals mutations in TRPV3 as a cause of Olmsted syndrome. Am J Hum Genet (2012) 1.91
Complete genome sequence of a highly prevalent isolate of porcine epidemic diarrhea virus in South China. J Virol (2012) 1.91
Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res (2009) 1.89
Changes in HIV prevalence and sexual behavior among men who have sex with men in a northern Chinese city: 2002-2006. J Infect (2007) 1.86
Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem (2009) 1.85
Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. Alzheimer Dis Assoc Disord (2006) 1.85
Lifestyle intervention development study to improve physical function in older adults with cancer: outcomes from Project LEAD. J Clin Oncol (2006) 1.84
Mechanisms of anterior cruciate ligament injury in World Cup alpine skiing: a systematic video analysis of 20 cases. Am J Sports Med (2011) 1.83